So, it was a healthy start to the year, M&A-wise, for one of the worst-performing sectors of the S&P 500® in 2024. The Health ...

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture capital firm , discusses how AI’s uptake in healthcare will shape its ...

Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge the company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.

Let's look at five pharma and drug companies ... at where Eli Lilly and Company (NYSE:LLY) stands against the other dividend stocks. During a time of great excitement about AI-driven capital ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA ... progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor.

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...

Follow along for live updates on stocks, bonds and markets, including the Dow Jones Industrial Average, S&P 500 and Nasdaq Composite.

Sanofi is tapping San Francisco-based Atomwise for a new AI-fuelled drug discovery deal ... including Merck & Co, Eli Lilly, and AbbVie. In 2019 they struck a major deal with China's Hansoh ...

As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer ...

A recent Morgan Stanley Research report suggested that even modest improvements in early-stage drug development success rates with AI and machine ... with pharma groups Eli Lilly and Merck ...

H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (NASDAQ:SLN) stock with a price target of $75.00, representing significant upside from the current price of $5.33. According to ...